Further, the cancer prevention effect has been supported by a recent retrospective cohort study that showed the protective effects of GLP‐1 receptor agonists against CRC among people with type 2 diabetes and obesity [76]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.